Every source has a job.

01 / Provider offer

Checked 2026-09-27

CoreAge Rx: Spot On ↗

Provider overview for the compounded product. Current plan strengths and totals are documented separately from the final offer page; individualized dispensing is not verified.

02 / Provider offer

Checked 2026-09-26

Musely: The Spot Cream ↗

Current two-month auto-refill presentation and self-reported outcomes; no independent trial audit.

03 / Provider formula

Checked 2026-09-26

Musely: Spot Cream formulas ↗

Formula options, initial-fill steroid notes and prescriber discretion. The Nurture list differs from the separate melasma article.

04 / Provider terms

Checked 2026-09-26

Musely: melasma treatment details ↗

$72 two-month auto-refill supply, $20 doctor visit and 60-day consultation period. Provider claims about clinical superiority or pregnancy are not adopted as personalized advice.

05 / Provider terms

Checked 2026-09-26

Musely: 60-Day Result Guarantee ↗

Initial-medication refund conditions and exclusions; not a medical instruction to continue through a reaction.

06 / Provider offer

Checked 2026-09-26

Dermatica: US prescription service ↗

28-day trial with a $4.99 prescribing fee advertised; check the selected US offer and eligibility.

07 / Provider formula

Checked 2026-09-26

Dermatica: melasma treatment ↗

Ingredient options and two-bottle delivery at approximately 56-day intervals; not a fixed formula for every patient.

08 / Provider terms

Checked 2026-09-26

Dermatica: pricing ↗

$29.95 per bottle and $59.90 every two months on the displayed plan; preserve the billing units.

09 / Provider formula

Checked 2026-09-26

Dermatica: ingredients ↗

Hydroquinone 4% listed among available ingredients; actual prescribing remains individual.

10 / Provider offer

Checked 2026-09-26

Skin Medicinals: care pathway ↗

Office evaluation, clinician selection and subsequent patient billing and shipping request.

11 / Provider formula

Checked 2026-09-26

Skin Medicinals: hyperpigmentation ↗

Several hydroquinone strengths and a $48-plus display; not one universal combination or all-in monthly quote.

12 / Provider terms

Checked 2026-09-26

Skin Medicinals: shipping and returns ↗

Policy dated August 18, 2026. Prescription shipping varies by pharmacy; separate retail-shop terms should not be blended with prescription rules.

13 / Regulatory reference

Checked 2026-09-27

FDA: skin product safety ↗

OTC hydroquinone sales, prescription distinction and reported harms; not a quality finding about a named reviewed cream.

14 / Regulatory reference

Checked 2026-09-26

FDA: OTC skin-lightening communication ↗

2022 communication explains the OTC issue and the approval of Tri-Luma; historical date retained.

15 / Regulatory reference

Checked 2026-09-26

FDA: compounded-drug risks ↗

Compounded preparations are not FDA-approved finished drugs. Category context does not prove a particular product has a defect.

16 / Regulatory reference

Checked 2026-09-27

FDA: state-licensed pharmacy lookup ↗

State-board links and consumer checks; this publication has not audited each potential dispenser.

17 / Medical reference

Checked 2026-09-27

AAD: melasma diagnosis and treatment ↗

Diagnosis and individualized care context; not comparative evidence for reviewed providers.

18 / Medical reference

Checked 2026-09-26

AAD: melasma self-care ↗

Sun protection, visible light and irritation considerations within melasma care.

19 / Medical reference

Checked 2026-09-27

AAD: fading dark spots ↗

Underlying causes and pigmentation after inflammation; product-list language is not a diagnosis.

20 / Medical reference

Checked 2026-09-26

AAD: pregnancy skincare ↗

Hydroquinone is listed among ingredients to avoid during pregnancy; individual circumstances need clinical discussion.

21 / Medicine label

Checked 2026-10-21

DailyMed: Tri-Luma label ↗

Defined three-drug product, indication and limits; its label and evidence should not be transferred to other compounded formulas.

22 / Manufacturer product

Checked 2026-09-26

Obagi: Nu-Derm Clear prescription page ↗

4% hydroquinone and physician-led purchase route. Current Rx price/stock not established; inactive list differs from historical DailyMed Clear record.

23 / Historical medicine label

Checked 2026-09-27

DailyMed: Obagi Clear, Blender and Sunfader label ↗

Insert revised March 2018; 4% Clear and 57 g packaging. Explicitly not FDA-approved. Historical package information is not current local stock or a resolved formula match.

24 / Manufacturer product

Checked 2026-09-26

Obagi: Clear Fx cosmetic page ↗

Arbutin cosmetic with $125 display; separate from hydroquinone Clear Rx. Its reviews, price and directions are not transferred to the prescription cream.

25 / Medical reference

Checked 2026-09-26

AAD: contact dermatitis assessment ↗

Clinical history, exposures and assessment of contact dermatitis; not a diagnosis of a reader or proof that a named product caused a rash.

26 / Medical reference

Checked 2026-09-26

AAD: medical patch testing ↗

Diagnostic patch testing differs from a home product check. Clinical interpretation and follow-up remain necessary.

27 / Medical reference

Checked 2026-09-26

AAD: photographs for a dermatologist ↗

Views, lighting, focus, privacy and clinician-selected frequency; does not validate home percentage-improvement measurements.

28 / Medical reference

Checked 2026-09-26

AAD: prepare for a telemedicine appointment ↗

Medication/allergy history, skin preparation and secure communication; no finding that every concern can be assessed remotely.

29 / Medical reference

Checked 2026-09-26

MedlinePlus: storing medicines ↗

General storage, changed appearance, travel and child-safety advice. Product-specific instructions and pharmacy advice take priority.

30 / Regulatory reference

Checked 2026-09-26

FDA: expired medicines ↗

Avoid expired medicines and use suitable disposal. Does not establish the shelf life or shipping tolerance of a particular cream.

31 / Medical reference

Checked 2026-09-26

LactMed: hydroquinone during breastfeeding ↗

Revised March 15, 2026. No breastfeeding studies or relevant drug-level data found; not contraindicated, with some experts discouraging long-term use. Avoid infant contact if used under care.

32 / Medical reference

Checked 2026-09-26

AAD: ABCDEs of melanoma ↗

Changing, unusual, itchy or bleeding marks need assessment. The checklist does not certify a lesion as harmless or replace an examination.

33 / Manufacturer product

Checked 2026-09-27

Obagi: Nu-Derm Blender prescription page ↗

4% hydroquinone and physician purchase route. Current Rx price and stock unverified; does not list tretinoin as an active ingredient.

34 / Historical medicine label

Checked 2026-09-27

Obagi: linked Clear, Blender and Sunfader insert ↗

PDF marked revised July 2010, still linked from the current page. Blender 57 g/28.5 g historical sizes and instructions are not merged with March 2018 DailyMed wording or treated as current inventory.

35 / Manufacturer product

Checked 2026-09-27

Obagi: Blend Fx cosmetic ↗

Hydroquinone-free arbutin cosmetic, $125 display. Price, customer ratings and AI-generated review summary are not evidence about Blender Rx.

36 / Medical reference

Checked 2026-09-27

AAD: chemical-peel consultation preparation ↗

Questions about practitioner experience, medical history and prior treatments. No personalized preparation or medication changes supplied here.

37 / Medical reference

Checked 2026-09-27

AAD: chemical-peel questions and recovery ↗

Different procedure depths and care needs; risks and clinical instructions, not a universal pause or restart schedule.

38 / Medical reference

Checked 2026-09-27

AAD: chemical-peel overview ↗

Procedure context and the professional-supervision warning. Does not establish that every pigment concern needs a peel.

39 / Regulatory reference

Checked 2026-09-27

FDA: chemical-peel products without professional supervision ↗

July 30, 2024 alert about high-concentration products and serious injury. No home concentration or dilution protocol inferred.

40 / Regulatory reference

Checked 2026-10-21

FDA: tested skin products containing mercury or hydroquinone ↗

Current table includes 2026 findings about specified products and sellers. Absence is not clearance; no contamination finding inferred about reviewed brands.

41 / Regulatory reference

Checked 2026-09-27

FDA: mercury poisoning linked to skin products ↗

Household exposure, medical/Poison Center advice and local disposal guidance. A safety report is not a diagnosis or an immediate care service.

42 / Provider offer

Checked 2026-09-27

CoreAge Rx: current Spot On offer ↗

Cards name hydroquinone 6% and kojic acid 6%, with niacinamide strength unspecified. $165/three months and $70/one month; separate $42 formula-block claim conflicts. Shipment/refund claims untested.

43 / Manufacturer product

Checked 2026-09-27

Cyspera US: Intensive current product ↗

TinyFish retrieved 7% cysteamine rinse-off description, full ingredient list and $180 display. A separate direct request returned 404; no checkout, regional eligibility or delivered package verified.

44 / Manufacturer catalog

Checked 2026-09-27

Cyspera US: current collection ↗

Current Intensive listing shows $180. Do not blend older system prices or different Cyspera versions into this record.

45 / Primary trial abstract

Checked 2026-09-27

Nguyen et al.: cysteamine and hydroquinone randomized trial ↗

Twenty recruited, fourteen completed; nonsignificant between-group result and more side effects with cysteamine. Abstract reviewed, not full methods; no exact-current-7%-product equivalence established.

46 / Research review abstract

Checked 2026-09-27

Ishack and Lipner: hydroquinone-associated ochronosis review ↗

126 patients in 56 published articles; selected case evidence cannot estimate population incidence or establish a risk-free concentration or duration.

47 / Primary case report

Checked 2026-09-27

Qorbani et al.: exogenous ochronosis case report (2020) ↗

Full text retrieved through Europe PMC after empty PMC extraction. Two exogenous cases and an endogenous comparison; historical regulatory discussion is not used as current US policy.

48 / Provider offer

Checked 2026-10-04

Likeness Rx — Dark Spot Cream ↗

Official product ingredients, displayed prices and subscription renewal, checked October 4, 2026. No patient care or fulfillment test performed.

49 / Provider shipping reference and supplied service information

Checked 2026-10-11

CoreAge Rx: shipping and service information ↗

Homepage shipping reference; customer service and payment details supplied for this review, without a checkout or timed support test

50 / Manufacturer public record

Checked 2026-10-13

Obagi: Clear prescription record — October check ↗

Current manufacturer record names prescription 4% hydroquinone and a physician-mediated purchase route. No direct Rx price, current local stock or delivered package verified.

51 / Manufacturer public record

Checked 2026-10-13

Obagi: Clear Fx cosmetic offer — October check ↗

Current Clear Fx arbutin cosmetic listing displays $125; this is separate from hydroquinone Clear Rx. No purchase or product-use test performed.

52 / Scientific evidence

Checked 2026-10-21

Efficacy and Safety of Generic Fluocinolone Acetonide, Hydroquinone, and Tretinoin Cream Compared With TRI-LUMA for the Treatment of Moderate-To-Severe Melasma in Chinese Patients: A Randomized, Single-Center, Placebo-Controlled Trial. ↗

Full research article, with indexed abstract where available

53 / Scientific evidence

Checked 2026-10-21

Comparison of Visible Light-Protective Tinted Sunscreen to Untinted Sunscreen to Protect Melasma Patients During Summer: A Prospective Randomized Investigator-Blinded Study. ↗

Full primary research letter plus verified PMC funding footnote; supporting-information document and figure-derived numerical data not reviewed